ARTICLE | Company News
arGentis, University of Tennessee deal
November 16, 2009 8:00 AM UTC
arGentis received exclusive, worldwide rights to the university's ARG301 to treat rheumatoid arthritis. The oral synthetic peptide targeting Type II collagen is in preclinical development. Financial ...